Skip to main content

Table 2 Demographics and baseline characteristics (full analysis set)

From: A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy

Characteristic

FMS/ALD + RSVa

(n = 43)

FMS/ALDb

(n = 45)

FMS + RSVc

(n = 43)

P-valued

Demographic

Age (yr)

59.65 ± 7.43

60.84 ± 6.29

60.74 ± 6.85

0.743

Age group (yr)

   

0.631

 19–64

30 ± 69.77

27 ± 60.00

28 ± 65.12

 

 ≥ 65

13 ± 30.23

18 ± 40.00

15 ± 34.88

 

Sex

   

0.542

 Male

32 (74.42)

36 (80.00)

30 (69.77)

 

 Female

11 (25.58)

9 (20.00)

13 (30.23)

 

Weight (kg)

73.14 ± 12.70

71.29 ± 10.01

74.53 ± 11.52

0.335

Height (cm)

164.87 ± 8.08

164.84 ± 7.67

164.81 ± 8.37

0.999

BMI (kg/m2)

   

0.202

 ≥ 18.5 to < 23

3 (6.98)

7 (15.56)

1 (2.33)

 

  ≥ 23 to < 25

7 (16.28)

10 (22.22)

8 (18.60)

 

  ≥ 25 to < 30

28 (65.12)

25 (55.56)

25 (58.14)

 

  ≥ 30

5 (11.63)

3 (6.67)

9 (20.93)

 

Smoke

   

0.548

 Smoker

11 (25.58)

12 (26.67)

12 (27.91)

 

 Nonsmoker

17 (39.53)

17 (37.78)

22 (51.16)

 

 Ex-smoker

15 (34.88)

16 (35.56)

9 (20.93)

 

Drink

   

0.385

 Drinker

26 (60.47)

26 (57.78)

20 (46.51)

 

 Nondrinker

17 (39.53)

19 (42.22)

23 (53.49)

 

Baseline characteristic

 SiSBP (mmHg)

153.98 ± 10.29

152.93 ± 8.69

152.52 ± 8.56

0.912

 SiDBP (mmHg)

89.71 ± 8.01

90.69 ± 8.61

94.41 ± 7.53

0.019

 LDL-C (mg/dL)

157.21 ± 27.45

151.22 ± 32.86

157.95 ± 36.43

0.566

 TC (mg/dL)

221.77 ± 28.38

213.51 ± 35.56

223.77 ± 40.14

0.348

 TG (mg/dL)

196.42 ± 79.24

180.53 ± 63.86

188.40 ± 75.13

0.769

 HDL-C (mg/dL)

48.44 ± 13.65

45.93 ± 12.07

48.84 ± 10.59

0.361

 Pulse (beats/min)

74.65 ± 11.83

77.51 ± 12.69

77.23 ± 11.35

0.619

  1. Data are presented as mean ± standard deviation or number (%)
  2. BMI Body mass index, SiSBP Sitting systolic blood pressure, SiDBP Sitting diastolic blood pressure, LDL-C Low-density lipoprotein cholesterol, TC Total cholesterol, TG Triglyceride, HDL-C High-density lipoprotein cholesterol
  3. a FMS/ALD + RSV; study group, fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg treatment
  4. b FMS/ALD; control 1 group, fimasartan 60 mg/amlodipine 10 mg treatment
  5. c FMS + RSV; control 2 group, fimasartan 60 mg + rosuvastatin 20 mg treatment
  6. d Statistical methods testing for difference among treatment groups (ANOVA, Kruskal–Wallis test, chi-square test, or Fisher exact test)